Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026986 (
myelodysplastic syndrome
)
14,926
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Sweet syndrome
is a neutrophilic dermatosis that could be associated with malignancy, especially hematologic malignancy. Few studies have systematically elaborated on this disorder and its features related with hematologic malignancy.
Objective:
This study aimed to describe the clinicopathological characteristics, treatment, and outcome of
Sweet syndrome
and to evaluate patient characteristics associated with hematologic malignancy.
Methods:
We retrospectively reviewed patients with
Sweet syndrome
at the Department of Dermatology, the First Affiliated Hospital of Zhejiang University from October 2010 to February 2019.
Results:
The study included 37 patients (16 men and 21 women), with a mean age of 53 years. Ten patients (27%) were classified as having malignancy-associated
Sweet syndrome
: nine with a hematologic malignancy including acute myeloid leukemia (4/9, 44%),
myelodysplastic syndrome
(4/9, 44%), and multiple myeloma (1/9, 11%) and one with a solid tumor diagnosed with liver carcinoma. The mean hemoglobin and platelet levels (
P
= 0.007 and
P
= 0.013, respectively), were significantly lower in patients with hematologic malignancy than in those with
Sweet syndrome
only. No significant difference in histopathology was found between patients with and without hematologic malignancy. Systemic corticosteroids were the most frequently used treatment (24/37, 65%). Higher mortality was found in patients with hematologic malignancy.
Conclusion:
It is important to assess
Sweet syndrome
patients who have laboratory evidence of lower hemoglobin and platelet levels for a hematologic malignancy.
...
PMID:Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy. 3213 63
We report a patient with
Sweet syndrome
involving the pulmonary system in the context of
myelodysplastic syndrome
. Although
Sweet syndrome
may involve a variety of organ systems, the pulmonary system is rarely affected and can result in poor clinical outcomes, including acute respiratory distress syndrome. Both cutaneous and pulmonary symptoms respond well to systemic corticosteroid therapy and early diagnosis and treatment can improve the prognosis. Our case highlights the importance of collaboration between hematologists, dermatologists, and pulmonologists to facilitate effective diagnosis, triage, and treatment of these patients.
...
PMID:Sweet syndrome with pulmonary involvement in a patient with myelodysplastic syndrome. 3260 50
Myelodysplastic syndromes
(
MDS
) are malignant hematopoietic stem cell disorders characterized by dysplastic and ineffective blood cell production leading to blood cytopenias, and a risk of transformation to acute myeloid leukemia (AML). Skin lesions in patients with
MDS
include
Sweet syndrome
(SS), leucocytoclastic vasculitis, leukemia cutis and histiocytoid SS (H-SS), among others,.
1,2
H-SS is a histological variant of SS differing from classical neutrophilic SS by a dermal infiltrate mostly made of immature cells of the myeloid lineage, that has been associated with myeloid malignancies.
...
PMID:Identification of Clonal Skin Myeloid Cells by Next Generation Sequencing in Myelodysplasia Cutis. 3296 12
<< Previous
1
2
3
4
5
6
7
8
9